Peter Jenner

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Activities & Behaviors

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Schapira A H; Agid Y; Barone P; Jenner P; Lemke M R; Poewe W; Rascol O; Reichmann H; Tolosa E
Perspectives on recent advances in the understanding and treatment of Parkinson's disease.
Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Schapira A H V; Emre M; Jenner P; Poewe W
Levodopa in the treatment of Parkinson's disease.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Jenner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Schapira A H; Agid Y; Barone P; Jenner P; Lemke M R; Poewe W; Rascol O; Reichmann H; Tolosa E
Perspectives on recent advances in the understanding and treatment of Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(10):1090-9.
2009: Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Experimental neurology 2009;219(2):533-42.
2009: Schapira A H V; Emre M; Jenner P; Poewe W
Levodopa in the treatment of Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(9):982-9.
2009: Jenner P; Mori A; Hauser R; Morelli M; Fredholm B B; Chen J F
Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Parkinsonism & related disorders 2009;15(6):406-13.
2009: Bukhatwa Salma; Iravani Mahmoud M; Zeng Bai-Yun; Cooper Jonathan D; Rose Sarah; Jenner Peter
An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat.
Journal of neurochemistry 2009;109(1):52-9.
2009: Morelli Micaela; Carta Anna R; Jenner Peter
Adenosine A2A receptors and Parkinson's disease.
Handbook of experimental pharmacology 2009;(193):589-615.
2008: Jenner Peter
Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
Annals of neurology 2008;64 Suppl 2():S16-29.
2008: Jenner Peter
Molecular mechanisms of L-DOPA-induced dyskinesia.
Nature reviews. Neuroscience 2008;9(9):665-77.
2008: Jenner P
Dopamine agonists in Parkinson's disease--focus on non-motor symptoms.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15 Suppl 2():1.
2008: Iravani Mahmoud M; Sadeghian Mona; Leung Clement C M; Tel Banu C; Rose Sarah; Schapira Anthony H; Jenner Peter
Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.
Experimental neurology 2008;212(2):522-31.
2008: MacInnes Nicholas; Iravani Mahmoud M; Perry Elaine; Piggott Margaret; Perry Robert; Jenner Peter; Ballard Clive
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(6):869-78.
2008: Stockwell K A; Virley D J; Perren M; Iravani M M; Jackson M J; Rose S; Jenner P
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Experimental neurology 2008;211(1):172-9.
2008: Jenner Peter
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Movement disorders : official journal of the Movement Disorder Society 2008;23 Suppl 3():S585-98.
2008: Lane E L; Cheetham S; Jenner P
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(3):423-9.
2007: Zubair Mohammed; Jackson Michael J; Tayarani-Binazir Kayhan; Stockwell Kim A; Smith Lance A; Rose Sarah; Olanow Warren; Jenner Peter
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Experimental neurology 2007;208(2):177-84.
2007: Iczkiewicz Joanna; Rose Sarah; Jenner Peter
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Experimental neurology 2007;207(1):95-106.
2007: Kuoppamäki M; Al-Barghouthy G; Jackson M J; Smith L A; Quinn N; Jenner P
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(9):1147-53.
2007: Hurley M J; Patel P H; Jackson M J; Smith L A; Rose S; Jenner P
Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
The European journal of neuroscience 2007;26(1):171-7.
2007: Litvan Irene; Chesselet Marie-Francoise; Gasser Thomas; Di Monte Donato A; Parker Davis; Hagg Theo; Hardy John; Jenner Peter; Myers Richard H; Price Donald; Hallett Mark; Langston William J; Lang Anthony E; Halliday Glenda; Rocca Walter; Duyckaerts Charles; Dickson Dennis W; Ben-Shlomo Yoav; Goetz Christopher G; Melamed Eldad
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.
Journal of neuropathology and experimental neurology 2007;66(5):329-36.
2007: Litvan Irene; Halliday Glenda; Hallett Mark; Goetz Christopher G; Rocca Walter; Duyckaerts Charles; Ben-Shlomo Yoav; Dickson Dennis W; Lang Anthony E; Chesselet Marie-Francoise; Langston William J; Di Monte Donato A; Gasser Thomas; Hagg Theo; Hardy John; Jenner Peter; Melamed Eldad; Myers Richard H; Parker Davis; Price Donald L
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.
Journal of neuropathology and experimental neurology 2007;66(4):251-7.
2007: Katzenschlager Regina; Jackson Michael J; Rose Sarah; Stockwell Kim; Tayarani-Binazir Kayhan A; Zubair Mohammed; Smith Lance A; Jenner Peter; Lees Andrew J
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Movement disorders : official journal of the Movement Disorder Society 2007;22(5):715-9.
2007: Rose Sarah; Scheller Dieter K A; Breidenbach Alexander; Smith Lance; Jackson Michael; Stockwell Kim; Jenner Peter
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates.
Behavioural pharmacology 2007;18(2):155-60.
2007: Jackson Michael J; Smith Lance A; Al-Barghouthy Ghassan; Rose Sarah; Jenner Peter
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Experimental neurology 2007;204(1):162-70.
2007: Rose Sarah; Ramsay Croft Neil; Jenner Peter
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Brain research 2007;1133(1):110-4.
2007: Jenner Peter
Oxidative stress and Parkinson's disease.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;83():507-20.
2006: Iravani Mahmoud M; Tayarani-Binazir Kayhan; Chu Wing B; Jackson Michael J; Jenner Peter
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
The Journal of pharmacology and experimental therapeutics 2006;319(3):1225-34.
2006: Iczkiewicz Joanna; Jackson Michael J; Smith Lance A; Rose Sarah; Jenner Peter
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.
Brain research 2006;1118(1):239-50.
2006: Schapira Anthony H V; Bezard Erwan; Brotchie Jonathan; Calon Frédéric; Collingridge Graham L; Ferger Borris; Hengerer Bastian; Hirsch Etienne; Jenner Peter; Le Novère Nicolas; Obeso José A; Schwarzschild Michael A; Spampinato Umberto; Davidai Giora
Novel pharmacological targets for the treatment of Parkinson's disease.
Nature reviews. Drug discovery 2006;5(10):845-54.
2006: Rose Sarah; Jackson Michael J; Smith Lance A; Stockwell Kim; Johnson Louisa; Carminati Paolo; Jenner Peter
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
European journal of pharmacology 2006;546(1-3):82-7.
2006: Hurley M J; Jenner P
What has been learnt from study of dopamine receptors in Parkinson's disease?
Pharmacology & therapeutics 2006;111(3):715-28.
2006: Zeng Bai-Yun; Bukhatwa Salma; Hikima Atsuko; Rose Sarah; Jenner Peter
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.
Annals of neurology 2006;60(2):248-52.
2006: Smith Lance A; Jackson Michael J; Johnston Louisa; Kuoppamaki Mikko; Rose Sarah; Al-Barghouthy Ghassan; Del Signore Susanna; Jenner Peter
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Clinical neuropharmacology 2006;29(3):112-25.
2006: Jenner Peter; Olanow C Warren
The pathogenesis of cell death in Parkinson's disease.
Neurology 2006;66(10 Suppl 4):S24-36.
2006: Zeng B-Y; Iravani M M; Lin S-T; Irifune M; Kuoppamäki M; Al-Barghouthy G; Smith L; Jackson M J; Rose S; Medhurst A D; Jenner P
MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.
The European journal of neuroscience 2006;23(7):1766-74.
2006: Iravani Mahmoud M; Haddon Claire O; Cooper J Mark; Jenner Peter; Schapira Anthony H
Pramipexole protects against MPTP toxicity in non-human primates.
Journal of neurochemistry 2006;96(5):1315-21.
2006: Carotti Angelo; Altomare Cosimo; Catto Marco; Gnerre Carmela; Summo Luciana; De Marco Agostino; Rose Sarah; Jenner Peter; Testa Bernard
Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.
Chemistry & biodiversity 2006;3(2):134-49.
2006: Lane E L; Cheetham S C; Jenner P
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Experimental neurology 2006;197(2):284-90.
2006: Iravani M M; Haddon C O; Rose S; Jenner P
3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor.
Brain research 2006;1067(1):256-62.
2005: Abd El Mohsen Manal M; Iravani Mahmoud M; Spencer Jeremy P E; Rose Sarah; Fahim Atef T; Motawi Tarek M K; Ismail Nabila A F; Jenner Peter
Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants.
Biochemical and biophysical research communications 2005;336(2):386-91.
2005: Hyun Dong-Hoon; Lee Moonhee; Halliwell Barry; Jenner Peter
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Journal of neuroscience research 2005;82(2):232-44.
2005: Iravani Mahmoud M; Costa Sergio; Al-Bargouthy Ghassan; Jackson Michael J; Zeng Bai-Yun; Kuoppamäki Mikko; Obeso Jose A; Jenner Peter
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
The European journal of neuroscience 2005;22(6):1305-18.
2005: Iravani Mahmoud M; Leung Clement C M; Sadeghian Mona; Haddon Claire O; Rose Sarah; Jenner Peter
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
The European journal of neuroscience 2005;22(2):317-30.
2005: Jenner Peter
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Neurology 2005;65(2 Suppl 1):S3-5.
2005: Hurley M J; Jackson M J; Smith L A; Rose S; Jenner P
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.
The European journal of neuroscience 2005;21(12):3240-50.
2005: Jenner Peter
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Expert opinion on investigational drugs 2005;14(6):729-38.
2005: Zeng B-Y; Medhurst A D; Jackson M; Rose S; Jenner P
Proteasomal activity in brain differs between species and brain regions and changes with age.
Mechanisms of ageing and development 2005;126(6-7):760-6.
2005: Dass B; Iravani M M; Huang C; Barsoum J; Engber T M; Galdes A; Jenner P
Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat.
Journal of neural transmission (Vienna, Austria : 1996) 2005;112(6):763-78.
2005: Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz M C; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin M R; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso J A
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination.]
Neurología (Barcelona, Spain) 2005;20(4):180-8.
2005: Iczkiewicz Joanna; Rose Sarah; Jenner Peter
Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat.
The European journal of neuroscience 2005;21(7):1911-20.
2005: Lane E L; Cheetham S; Jenner P
Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1124-31.
2005: Smith Lance A; Jackson Michael J; Al-Barghouthy Ghassan; Rose Sarah; Kuoppamaki Mikko; Olanow Warren; Jenner Peter
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Movement disorders : official journal of the Movement Disorder Society 2005;20(3):306-14.
2005: Iravani Mahmoud M; Syed Emilie; Jackson Michael J; Johnston Louisa C; Smith Lance A; Jenner Peter
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
The European journal of neuroscience 2005;21(4):841-54.
2005: Lane E L; Cheetham S C; Jenner P
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
The European journal of neuroscience 2005;21(1):179-86.
2004: Gu Mei; Iravani M M; Cooper J Mark; King Diane; Jenner Peter; Schapira Anthony H V
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.
Journal of neurochemistry 2004;91(5):1075-81.
2004: Iczkiewicz Joanna; Rose Sarah; Jenner Peter
Osteopontin (Eta-1) is present in the rat basal ganglia.
Brain research. Molecular brain research 2004;132(1):64-72.
2004: Iravani Mahmoud M; Liu Lin; Rose Sarah; Jenner Peter
Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration.
Brain research 2004;1029(1):103-13.
2004: Zeng B-Y; Heales S J R; Canevari L; Rose S; Jenner P
Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice.
Experimental neurology 2004;190(2):515-24.
2004: Jackson Michael J; Al-Barghouthy Ghassan; Pearce Ronald K B; Smith Lance; Hagan James J; Jenner Peter
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Pharmacology, biochemistry, and behavior 2004;79(3):391-400.
2004: Jenner Peter
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Neurology 2004;63(7 Suppl 2):S13-22.
2004: Olanow C Warren; Agid Yves; Mizuno Yoshi; Albanese Alberto; Bonuccelli Ubaldo; Damier Philip; De Yebenes Justo; Gershanik Oscar; Guttman Mark; Grandas F; Hallett Mark; Hornykiewicz Ole; Jenner Peter; Katzenschlager R; Langston William J; LeWitt Peter; Melamed Eldad; Mena M A; Michel P P; Mytilineou Catherine; Obeso Jose A; Poewe Werner; Quinn Niall; Raisman-Vozari R; Rajput Ali H; Rascol Olivier; Sampaio Christina; Stocchi Fabrizio
Levodopa in the treatment of Parkinson's disease: current controversies.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):997-1005.
2004: Hyun Dong-Hoon; Gray Douglas A; Halliwell Barry; Jenner Peter
Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases.
Journal of neurochemistry 2004;90(2):422-30.
2004: Millan Mark J; Di Cara Benjamin; Hill Michael; Jackson Michael; Joyce Jeffrey N; Brotchie Jonathan; McGuire Steve; Crossman Alan; Smith Lance; Jenner Peter; Gobert Alain; Peglion Jean-Louis; Brocco Mauricette
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):921-35.
2004: Löschmann Peter-Andreas; De Groote Carmen; Smith Lance; Wüllner Ullrich; Fischer Günther; Kemp John A; Jenner Peter; Klockgether Thomas
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Experimental neurology 2004;187(1):86-93.
2004: Whitehead K J; Rose S; Jenner P
Halothane anesthesia affects NMDA-stimulated cholinergic and GABAergic modulation of striatal dopamine efflux and metabolism in the rat in vivo.
Neurochemical research 2004;29(4):835-42.
2004: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Movement disorders : official journal of the Movement Disorder Society 2004;19(1):15-21.
2004: Jenner Peter
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Neurology 2004;62(1 Suppl 1):S47-55.
2004: Zeng B-Y; Smith L A; Pearce R K B; Tel B; Chancharme L; Moachon G; Jenner P
Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets.
Neuroscience letters 2004;354(1):6-9.
2003: Jenner Peter
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Current opinion in neurology 2003;16 Suppl 1():S3-7.
2003: Kase Hiroshi; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson P J; Jenner P; Bedard P; Borrelli E; Hauser R A; Chase T N;
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Neurology 2003;61(11 Suppl 6):S97-100.
2003: Jenner Peter
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.
Neurology 2003;61(11 Suppl 6):S32-8.
2003: Hurley M J; Mash D C; Jenner P
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(11):1279-88.
2003: Hurley Michael J; Mash Deborah C; Jenner Peter
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
The European journal of neuroscience 2003;18(9):2668-72.
2003: Iravani Mahmoud M; Jackson Michael J; Kuoppamäki Mikko; Smith Lance A; Jenner Peter
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(27):9107-15.
2003: Gilbert E A; Edwards R J; Boobis A R; Rose S; Jenner P
Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(10):1091-101.
2003: Jenner Peter
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Neurology 2003;61(6 Suppl 3):S4-11.
2003: Hyun Dong-Hoon; Lee MoonHee; Halliwell Barry; Jenner Peter
Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins.
Journal of neurochemistry 2003;86(2):363-73.
2003: Schwarz M J; Houghton P J; Rose S; Jenner P; Lees A D
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism.
Pharmacology, biochemistry, and behavior 2003;75(3):627-33.
2003: Smith Lance A; Jackson Michael J; Hansard Matthew J; Maratos Eleni; Jenner Peter
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Movement disorders : official journal of the Movement Disorder Society 2003;18(5):487-95.
2003: Kunikowska Grazyna; Jenner Peter
Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Brain research 2003;968(2):206-18.
2003: Silva M T; Rose S; Hindmarsh J G; Jenner P
Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(4):353-62.
2003: Treseder S A; Rose S; Summo L; Jenner P
Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(3):229-38.
2003: Cannizzaro Carla; Tel Banu C; Rose Sarah; Zeng Bai-Yun; Jenner Peter
Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease.
Brain research. Molecular brain research 2003;110(2):169-76.
2003: Jenner Peter
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
Parkinsonism & related disorders 2003;9(3):131-7.
2003: Maratos Eleni C; Jackson Michael J; Pearce Ronald K B; Cannizzaro Carla; Jenner Peter
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Experimental neurology 2003;179(1):90-102.
2003: McNaught Kevin St P; Belizaire Roger; Isacson Ole; Jenner Peter; Olanow C Warren
Altered proteasomal function in sporadic Parkinson's disease.
Experimental neurology 2003;179(1):38-46.
2003: Jenner Peter
Oxidative stress in Parkinson's disease.
Annals of neurology 2003;53 Suppl 3():S26-36; discussion S36-8.
2002: Abd El Mohsen Manal M; Kuhnle Gunter; Rechner Andreas R; Schroeter Hagen; Rose Sarah; Jenner Peter; Rice-Evans Catherine A
Uptake and metabolism of epicatechin and its access to the brain after oral ingestion.
Free radical biology & medicine 2002;33(12):1693-702.
2002: McNaught Kevin St P; Shashidharan P; Perl Daniel P; Jenner Peter; Olanow C Warren
Aggresome-related biogenesis of Lewy bodies.
The European journal of neuroscience 2002;16(11):2136-48.
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of pharmacology and experimental therapeutics 2002;303(3):952-8.
2002: Kuoppamäki Mikko; Al-Barghouthy Ghassan; Jackson Michael; Smith Lance; Zeng Bai-Yun; Quinn Niall; Jenner Peter
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Movement disorders : official journal of the Movement Disorder Society 2002;17(6):1312-7.
2002: Hyun Dong-Hoon; Lee Moon-Hee; Halliwell Barry; Jenner Peter
Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?
Journal of neurochemistry 2002;83(2):360-70.
2002: Kunikowska Grazyna; Gallagher Imelda; Glover Vivette; Clow Angela; Jenner Peter
Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain.
Brain research 2002;953(1-2):1-11.
2002: Smith Lance A; Tel Banu C; Jackson Michael J; Hansard Matthew J; Braceras Rogelio; Bonhomme Céline; Chezaubernard Claire; Del Signore Susanna; Rose Sarah; Jenner Peter
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):887-901.
2002: Pearce Ronald K B; Smith Lance A; Jackson Michael J; Banerji Tara; Scheel-Krüger Jorgen; Jenner Peter
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):877-86.
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
European journal of pharmacology 2002;451(2):157-60.
2002: McNaught Kevin St P; Björklund Lars M; Belizaire Roger; Isacson Ole; Jenner Peter; Olanow C Warren
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
Neuroreport 2002;13(11):1437-41.
2002: Hyun Dong-Hoon; Lee MoonHee; Hattori Nobutaka; Kubo Shin-Ichiro; Mizuno Yoshikuni; Halliwell Barry; Jenner Peter
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.
The Journal of biological chemistry 2002;277(32):28572-7.
2002: McNaught Kevin St P; Belizaire Roger; Jenner Peter; Olanow C Warren; Isacson Ole
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.
Neuroscience letters 2002;326(3):155-8.
2002: Spencer Jeremy P E; Whiteman Matthew; Jenner Peter; Halliwell Barry
5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons.
Journal of neurochemistry 2002;81(1):122-9.
2002: Zeng B-Y; Dass B; Owen A; Rose S; Cannizzaro C; Tel B C; Jenner P
6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats.
Neuroscience letters 2002;322(1):33-6.
2002: Kunikowska Grazyna; Jenner Peter
The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.
Biochemical pharmacology 2002;63(6):1159-64.
2002: Smith L A; Jackson M J; Al-Barghouthy G; Jenner P
The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(2):123-40.
2002: Jenner Peter
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
Neurology 2002;58(4 Suppl 1):S1-8.
2002: Perry N S L; Houghton P J; Jenner P; Keith A; Perry E K
Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo.
Phytomedicine : international journal of phytotherapy and phytopharmacology 2002;9(1):48-51.
2002: Tel B C; Zeng B-Y; Cannizzaro C; Pearce R K B; Rose S; Jenner P
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Neuroscience 2002;115(4):1047-58.
2002: Dass B; Iravani M M; Jackson M J; Engber T M; Galdes A; Jenner P
Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Neuroscience 2002;114(1):99-109.
2002: Iravani M M; Kashefi K; Mander P; Rose S; Jenner P
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.
Neuroscience 2002;110(1):49-58.
2002: Lyras L; Zeng B-Y; McKenzie G; Pearce R K B; Halliwell B; Jenner P
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(1):53-67.
2001: Lastres-Becker I; Cebeira M; de Ceballos M L; Zeng B Y; Jenner P; Ramos J A; Fernández-Ruiz J J
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
The European journal of neuroscience 2001;14(11):1827-32.
2001: Lee M; Hyun D H; Marshall K A; Ellerby L M; Bredesen D E; Jenner P; Halliwell B
Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome.
Free radical biology & medicine 2001;31(12):1550-9.
2001: Kunikowska G; Jenner P
6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase.
Brain research 2001;922(1):51-64.
2001: Perry N S; Houghton P J; Sampson J; Theobald A E; Hart S; Lis-Balchin M; Hoult J R; Evans P; Jenner P; Milligan S; Perry E K
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease.
The Journal of pharmacy and pharmacology 2001;53(10):1347-56.
2001: Whitehead K J; Rose S; Jenner P
Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats.
The European journal of neuroscience 2001;14(5):851-60.
2001: Pearce R K; Heikkilä M; Lindén I B; Jenner P
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
Psychopharmacology 2001;156(4):402-9.
2001: McNaught K S; Olanow C W; Halliwell B; Isacson O; Jenner P
Failure of the ubiquitin-proteasome system in Parkinson's disease.
Nature reviews. Neuroscience 2001;2(8):589-94.
2001: Ferger B; Themann C; Rose S; Halliwell B; Jenner P
6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation.
Journal of neurochemistry 2001;78(3):509-14.
2001: Maratos E C; Jackson M J; Pearce R K; Jenner P
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Movement disorders : official journal of the Movement Disorder Society 2001;16(4):631-41.
2001: Lee M; Hyun D H; Halliwell B; Jenner P
Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative stress and cell death induced by hydrogen peroxide, 4-hydroxynonenal or serum deprivation: potentiation of injury by ALS-related mutant superoxide dismutases and protection by Bcl-2.
Journal of neurochemistry 2001;78(2):209-20.
2001: Lee M H; Hyun D H; Jenner P; Halliwell B
Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production.
Journal of neurochemistry 2001;78(1):32-41.
2001: Ferger B; Rose S; Jenner A; Halliwell B; Jenner P
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
Neuroreport 2001;12(6):1155-9.
2001: Jenner P
Parkinson's disease, pesticides and mitochondrial dysfunction.
Trends in neurosciences 2001;24(5):245-7.
2001: Hurley M J; Mash D C; Jenner P
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease.
Brain research. Molecular brain research 2001;87(2):271-9.
2001: Lee M; Hyun D; Halliwell B; Jenner P
Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.
Journal of neurochemistry 2001;76(4):998-1009.
2001: Lee M; Hyun D; Jenner P; Halliwell B
Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis.
Journal of neurochemistry 2001;76(4):957-65.
2001: Iravani M M; Costa S; Jackson M J; Tel B C; Cannizzaro C; Pearce R K; Jenner P
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
The European journal of neuroscience 2001;13(3):597-608.
2001: Costa S; Iravani M M; Pearce R K; Jenner P
Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
European journal of pharmacology 2001;412(1):45-50.
2001: McNaught K S; Jenner P
Proteasomal function is impaired in substantia nigra in Parkinson's disease.
Neuroscience letters 2001;297(3):191-4.
2001: Treseder S A; Rose S; Jenner P
The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
The European journal of neuroscience 2001;13(1):162-70.
2001: Zeng B Y; Pearce R K; MacKenzie G M; Jenner P
Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study.
Journal of neural transmission (Vienna, Austria : 1996) 2001;108(8-9):925-41.
2001: Medhurst A D; Zeng B Y; Charles K J; Gray J; Reavill C; Hunter A J; Shale J A; Jenner P
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Neuroscience 2001;105(2):353-64.
2001: McNaught K S; Lee M; Hyun D H; Jenner P
Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease.
Advances in neurology 2001;86():73-82.
2000: Riedl A G; Watts P M; Douek D C; Edwards R J; Boobis A R; Rose S; Jenner P
Expression and distribution of CYP2C enzymes in rat basal ganglia.
Synapse (New York, N.Y.) 2000;38(4):392-402.
2000: McNaught K S; Jenner P
Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation.
Biochemical pharmacology 2000;60(7):979-88.
2000: Treseder S A; Smith L A; Jenner P
Endogenous dopaminergic tone and dopamine agonist action.
Movement disorders : official journal of the Movement Disorder Society 2000;15(5):804-12.
2000: Hurley M J; Mash D C; Jenner P
Adenosine A(2A) receptor mRNA expression in Parkinson's disease.
Neuroscience letters 2000;291(1):54-8.
2000: Gallagher I M; Jenner P; Glover V; Clow A
CuZn-superoxide dismutase transgenic mice: no effect on longevity, locomotor activity and 3H-mazindol and 3H-spiperone binding over 19 months.
Neuroscience letters 2000;289(3):221-3.
2000: Alam Z I; Halliwell B; Jenner P
No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease.
Journal of neurochemistry 2000;75(2):840-6.
2000: Jenner P; Zeng B Y; Smith L A; Pearce R K; Tel B; Chancharme L; Moachon G
Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 2000;133(2):178-88.
2000: Perry N S; Houghton P J; Theobald A; Jenner P; Perry E K
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes.
The Journal of pharmacy and pharmacology 2000;52(7):895-902.
2000: Smith L A; Jackson M G; Bonhomme C; Chezaubernard C; Pearce R K; Jenner P
Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset.
Clinical neuropharmacology 2000;23(3):133-42.
2000: McNaught K S; Jenner P
Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release.
Neuroscience letters 2000;285(1):61-5.
2000: Jenner P
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments.
Journal of neurology 2000;247 Suppl 2():II43-50.
2000: Jenner P
Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
Annals of neurology 2000;47(4 Suppl 1):S90-9; discussion S99-104.
2000: Treseder S A; Jackson M; Jenner P
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
British journal of pharmacology 2000;129(7):1355-64.
2000: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Experimental neurology 2000;162(2):321-7.
2000: Zeng B Y; Pearce R K; MacKenzie G M; Jenner P
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
The European journal of neuroscience 2000;12(3):1096-104.
2000: Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn N P; Jenner P; Poewe W; Wenning G K
Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
Neuroscience 2000;95(2):377-88.
2000: Chadha A; Dawson L G; Jenner P G; Duty S
Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus.
Neuroscience 2000;95(1):119-26.
1999: Jenner P
Genetic susceptibility and the occurrence of Parkinson's disease.
Parkinsonism & related disorders 1999;5(4):173-7.
1999: Zeng B Y; Dass B; Owen A; Rose S; Cannizzaro C; Tel B C; Jenner P
Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
Neuroscience letters 1999;276(2):71-4.
1999: McNaught K S; Jenner P
Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
Journal of neurochemistry 1999;73(6):2469-76.
1999: Gallagher I M; Clow A; Jenner P; Glover V
Long-term effects of pergolide and (-)-deprenyl on 3H-mazindol and 3H-spiperone binding in rat brain.
Neurobiology of aging 1999;20(6):709-13.
1999: Marshall K A; Reist M; Jenner P; Halliwell B
The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease.
Free radical biology & medicine 1999;27(5-6):515-20.
1999: Dexter D T; Ward R J; Florence A; Jenner P; Crichton R R
Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Biochemical pharmacology 1999;58(1):151-5.
1999: Riedl A G; Watts P M; Edwards R J; Schulz-Utermoehl T; Boobis A R; Jenner P; Marsden C D
Expression and localisation of CYP2D enzymes in rat basal ganglia.
Brain research 1999;822(1-2):175-91.
1999: Pearce R K; Jackson M; Britton D R; Shiosaki K; Jenner P; Marsden C D
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Psychopharmacology 1999;142(1):51-60.
1999: Pearce R K; Costa S; Jenner P; Marsden C D
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.
Journal of neural transmission (Vienna, Austria : 1996) 1999;106(7-8):663-83.
1999: Rose S; Hindmarsh J G; Jenner P
Neuronal nitric oxide synthase inhibition reduces MPP+-evoked hydroxyl radical formation but not dopamine efflux in rat striatum.
Journal of neural transmission (Vienna, Austria : 1996) 1999;106(5-6):477-86.
1999: Riedl A G; Watts P M; Brown C T; Jenner P
P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease.
Advances in neurology 1999;80():271-86.
1999: Rose S; MacKenzie G M; Jenner P
Nitric oxide and basal ganglia degeneration.
Advances in neurology 1999;80():247-57.
1999: Kuwana Y; Shiozaki S; Kanda T; Kurokawa M; Koga K; Ochi M; Ikeda K; Kase H; Jackson M J; Smith L A; Pearce R K; Jenner P G
Antiparkinsonian activity of adenosine A2A antagonists in experimental models.
Advances in neurology 1999;80():121-3.
1998: Reist M; Marshall K A; Jenner P; Halliwell B
Toxic effects of sulphite in combination with peroxynitrite on neuronal cells.
Journal of neurochemistry 1998;71(6):2431-8.
1998: Spencer J P; Jenner P; Daniel S E; Lees A J; Marsden D C; Halliwell B
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Journal of neurochemistry 1998;71(5):2112-22.
1998: McNaught K S; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.
Biochemical pharmacology 1998;56(8):921-33.
1998: Watts P M; Riedl A G; Douek D C; Edwards R J; Boobis A R; Jenner P; Marsden C D
Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.
Neuroscience 1998;86(2):511-9.
1998: Olanow C W; Jenner P; Brooks D
Dopamine agonists and neuroprotection in Parkinson's disease.
Annals of neurology 1998;44(3 Suppl 1):S167-74.
1998: Jenner P; Olanow C W
Understanding cell death in Parkinson's disease.
Annals of neurology 1998;44(3 Suppl 1):S72-84.
1998: Howard M K; Kershaw T; Gibb B; Storey N; MacLean A R; Zeng B Y; Tel B C; Jenner P; Brown S M; Woolf C J; Anderson P N; Coffin R S; Latchman D S
High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5.
Gene therapy 1998;5(8):1137-47.
1998: Kanda T; Tashiro T; Kuwana Y; Jenner P
Adenosine A2A receptors modify motor function in MPTP-treated common marmosets.
Neuroreport 1998;9(12):2857-60.
1998: Lyras L; Perry R H; Perry E K; Ince P G; Jenner A; Jenner P; Halliwell B
Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies.
Journal of neurochemistry 1998;71(1):302-12.
1998: Gu M; Owen A D; Toffa S E; Cooper J M; Dexter D T; Jenner P; Marsden C D; Schapira A H
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Journal of the neurological sciences 1998;158(1):24-9.
1998: Jenner P G; Brin M F
Levodopa neurotoxicity: experimental studies versus clinical relevance.
Neurology 1998;50(6 Suppl 6):S39-43; discussion S44-8.
1998: Halliwell B; Jenner P
Impaired clearance of oxidised proteins in neurodegenerative diseases.
Lancet 1998;351(9114):1510.
1998: Kaur H; Lyras L; Jenner P; Halliwell B
Artefacts in HPLC detection of 3-nitrotyrosine in human brain tissue.
Journal of neurochemistry 1998;70(5):2220-3.
1998: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Annals of neurology 1998;43(4):507-13.
1998: Pearce R K; Banerji T; Jenner P; Marsden C D
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):234-41.
1998: Riedl A G; Watts P M; Jenner P; Marsden C D
P450 enzymes and Parkinson's disease: the story so far.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):212-20.
1998: Reist M; Jenner P; Halliwell B
Sulphite enhances peroxynitrite-dependent alpha1-antiproteinase inactivation. A mechanism of lung injury by sulphur dioxide?
FEBS letters 1998;423(2):231-4.
1998: Silva M T; Rose S; Hindmarsh J G; Jenner P; Marsden C D
L-arginine produces NO-independent increases in dopamine efflux in rat striatum.
Neuroreport 1998;9(1):149-52.
1998: Jenner P
Oxidative mechanisms in nigral cell death in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13 Suppl 1():24-34.
1997: Smith L A; Gordin A; Jenner P; Marsden C D
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Movement disorders : official journal of the Movement Disorder Society 1997;12(6):935-45.
1997: Marshall K A; Daniel S E; Cairns N; Jenner P; Halliwell B
Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease.
Biochemical and biophysical research communications 1997;240(1):84-7.
1997: Richardson P J; Kase H; Jenner P G
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.
Trends in pharmacological sciences 1997;18(9):338-44.
1997: Alam Z I; Daniel S E; Lees A J; Marsden D C; Jenner P; Halliwell B
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.
Journal of neurochemistry 1997;69(3):1326-9.
1997: Alam Z I; Jenner A; Daniel S E; Lees A J; Cairns N; Marsden C D; Jenner P; Halliwell B
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra.
Journal of neurochemistry 1997;69(3):1196-203.
1997: Silva M T; Schapira A H; Jenner P
Unexpected findings of study of selegiline have not been treated with caution its authors advised.
BMJ (Clinical research ed.) 1997;315(7104):370.
1997: Mackenzie G M; Jackson M J; Jenner P; Marsden C D
Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Synapse (New York, N.Y.) 1997;26(3):301-16.
1997: Lyras L; Cairns N J; Jenner A; Jenner P; Halliwell B
An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease.
Journal of neurochemistry 1997;68(5):2061-9.
1997: Sian J; Dexter D T; Cohen G; Jenner P G; Marsden C D
Comparison of HPLC and enzymatic recycling assays for the measurement of oxidized glutathione in rat brain.
The Journal of pharmacy and pharmacology 1997;49(3):332-5.
1997: Gerlach M; Double K; Riederer P; Hirsch E; Jellinger K; Jenner P; Trautwein A; Youdim M B
Iron in the Parkinsonian substantia nigra.
Movement disorders : official journal of the Movement Disorder Society 1997;12(2):258-60.
1997: Rose S; Hindmarsh J G; Collins P; Jenner P
The effect of fenfluramine dosage regimen and reduced food intake on levels of 5-HT in rat brain.
Journal of neural transmission (Vienna, Austria : 1996) 1997;104(11-12):1339-51.
1997: Owen A D; Schapira A H; Jenner P; Marsden C D
Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies.
Journal of neural transmission. Supplementum 1997;51():167-73.
1997: Pearce R K; Owen A; Daniel S; Jenner P; Marsden C D
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 1997;104(6-7):661-77.
1997: Toffa S; Kunikowska G M; Zeng B Y; Jenner P; Marsden C D
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration.
Journal of neural transmission (Vienna, Austria : 1996) 1997;104(1):67-75.
1996: Riedl A G; Watts P M; Edwards R J; Boobis A R; Jenner P; Marsden C D
Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera.
Brain research 1996;743(1-2):324-8.
1996: Hurley M J; Stubbs C M; Jenner P; Marsden C D
Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics.
European journal of pharmacology 1996;318(2-3):283-93.
1996: Seaton T A; Jenner P; Marsden C D
Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat.
Biochemical pharmacology 1996;52(11):1657-63.
1996: Hurley M J; Stubbs C M; Jenner P; Marsden C D
Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain.
Psychopharmacology 1996;128(4):362-70.
1996: Jenner P; Olanow C W
Oxidative stress and the pathogenesis of Parkinson's disease.
Neurology 1996;47(6 Suppl 3):S161-70.
1996: McNaught K S; Thull U; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration 1996;5(3):265-74.
1996: Wenning G K; Granata R; Laboyrie P M; Quinn N P; Jenner P; Marsden C D
Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
Movement disorders : official journal of the Movement Disorder Society 1996;11(5):522-32.
1996: Hurley M J; Stubbs C M; Jenner P; Marsden C D
D3 receptor expression within the basal ganglia is not affected by Parkinson's disease.
Neuroscience letters 1996;214(2-3):75-8.
1996: Pearce R K; Collins P; Jenner P; Emmett C; Marsden C D
Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset.
Synapse (New York, N.Y.) 1996;23(3):192-200.
1996: McNaught K S; Thull U; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Biochemical pharmacology 1996;52(1):29-34.
1996: Rose S; Hunt S; Collins P; Hindmarsh J G; Jenner P
Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats.
Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration 1996;5(2):145-52.
1996: Owen A D; Schapira A H; Jenner P; Marsden C D
Oxidative stress and Parkinson's disease.
Annals of the New York Academy of Sciences 1996;786():217-23.
1996: Fernandez A; de Ceballos M L; Rose S; Jenner P; Marsden C D
Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Brain : a journal of neurology 1996;119 ( Pt 3)():823-30.
1996: Zeng B Y; Jenner P; Marsden C D
Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation.
Experimental neurology 1996;139(2):214-26.
1996: McNaught K S; Thull U; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration.
Biochemical pharmacology 1996;51(11):1503-11.
1996: Seaton T A; Jenner P; Marsden C D
The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia.
Biochemical pharmacology 1996;51(7):983-6.
1996: McNaught K S; Thull U; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neuroscience letters 1996;206(1):37-40.
1996: Smith L; De Salvia M; Jenner P; Marsden C D
An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Movement disorders : official journal of the Movement Disorder Society 1996;11(2):125-35.
1996: Silva M T; Watts P M; Jenner P
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
BMJ (Clinical research ed.) 1996;312(7032):703; author reply 704-5.
1996: Spencer J P; Jenner A; Butler J; Aruoma O I; Dexter D T; Jenner P; Halliwell B
Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease.
Free radical research 1996;24(2):95-105.
1996: Hurley M J; Jolkkonen J; Stubbs C M; Jenner P; Marsden C D
Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment.
Brain research 1996;709(2):259-64.
1996: Riedl A G; Watts P M; Edwards R J; Boobis A R; Jenner P
Brain cytochrome P450 in the rat.
Biochemical Society transactions 1996;24(1):52S.
1996: Zeng B Y; Jenner P; Marsden C D
Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery.
Movement disorders : official journal of the Movement Disorder Society 1996;11(1):43-52.
1996: Jenner P
Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
Pathologie-biologie 1996;44(1):57-64.
1996: Shiosaki K; Jenner P; Asin K E; Britton D R; Lin C W; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
The Journal of pharmacology and experimental therapeutics 1996;276(1):150-60.
1996: Seaton T A; Jenner P; Marsden C D
Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(3):315-29.
1996: Granata R; Wenning G K; Jolkkonen J; Jenner P; Marsden C D
Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(3):249-60.
1995: Pearce R K; Jackson M; Smith L; Jenner P; Marsden C D
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Movement disorders : official journal of the Movement Disorder Society 1995;10(6):731-40.
1995: McNaught K S; Thull U; Carrupt P A; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden C D
Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Biochemical pharmacology 1995;50(11):1903-11.
1995: Brunner-Guenat M; Carrupt P A; Lisa G; Testa B; Rose S; Thomas K; Jenner P; Ventura P
Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.
The Journal of pharmacy and pharmacology 1995;47(10):861-9.
1995: MacKenzie G M; Jenner P; Marsden C D
Effect of 7-nitro indazole on quinolinic acid-induced striatal toxicity in the rat.
Neuroreport 1995;6(13):1789-94.
1995: Thull U; Kneubühler S; Gaillard P; Carrupt P A; Testa B; Altomare C; Carotti A; Jenner P; McNaught K S
Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships.
Biochemical pharmacology 1995;50(6):869-77.
1995: Jolkkonen J; Jenner P; Marsden C D
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Brain research. Molecular brain research 1995;32(2):297-307.
1995: Jolkkonen J; Granata R; Jenner P; Marsden C D
Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum.
Neuropeptides 1995;29(2):109-14.
1995: Spencer J P; Jenner P; Halliwell B
Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease.
Neuroreport 1995;6(11):1480-4.
1995: MacKenzie G M; Jenner P; Marsden C D
The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum.
Neuroscience 1995;67(2):357-71.
1995: Ward R J; Dexter D; Florence A; Aouad F; Hider R; Jenner P; Crichton R R
Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism.
Biochemical pharmacology 1995;49(12):1821-6.
1995: Gnanalingham K K; Hunter A J; Jenner P; Marsden C D
Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour.
Biochemical pharmacology 1995;49(9):1185-93.
1995: McNaught K S; Altomare C; Cellamare S; Carotti A; Thull U; Carrupt P A; Testa B; Jenner P; Marsden C D
Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Neuroreport 1995;6(8):1105-8.
1995: Zeng B Y; Jolkkonen J; Jenner P; Marsden C D
Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.
Neuroscience 1995;66(1):19-28.
1995: Gnanalingham K K; Milkowski N A; Smith L A; Hunter A J; Jenner P; Marsden C D
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
European journal of pharmacology 1995;277(2-3):235-41.
1995: Jenner P
The rationale for the use of dopamine agonists in Parkinson's disease.
Neurology 1995;45(3 Suppl 3):S6-12.
1995: Gnanalingham K K; Hunter A J; Jenner P; Marsden C D
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Psychopharmacology 1995;117(3):287-97.
1995: Gnanalingham K K; Erol D D; Hunter A J; Smith L A; Jenner P; Marsden C D
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Psychopharmacology 1995;117(3):275-86.
1995: Gnanalingham K K; Hunter A J; Jenner P; Marsden C D
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Psychopharmacology 1995;117(4):403-12.
1995: Jeding I; Evans P J; Akanmu D; Dexter D; Spencer J D; Aruoma O I; Jenner P; Halliwell B
Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs.
Biochemical pharmacology 1995;49(3):359-65.
1995: Silva M T; Rose S; Hindmarsh J G; Aislaitner G; Gorrod J W; Moore P K; Jenner P; Marsden C D
Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole.
British journal of pharmacology 1995;114(2):257-8.
1995: Jolkkonen J; Jenner P; Marsden C D
Glutamatergic regulation of striatal peptide gene expression in rats.
Journal of neural transmission. Parkinson's disease and dementia section 1995;10(2-3):187-98.
1995: Gnanalingham K K; Milkowski N A; Smith L A; Hunter A J; Jenner P; Marsden C D
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.
Journal of neural transmission. General section 1995;101(1-3):65-82.
1995: Fernandez A; Jenner P; Marsden C D; De Ceballos M L
Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels in substantia nigra in Parkinson's disease.
Peptides 1995;16(2):339-46.
1994: Mann V M; Cooper J M; Daniel S E; Srai K; Jenner P; Marsden C D; Schapira A H
Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
Annals of neurology 1994;36(6):876-81.
1994: Spencer J P; Jenner A; Aruoma O I; Evans P J; Kaur H; Dexter D T; Jenner P; Lees A J; Marsden D C; Halliwell B
Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.
FEBS letters 1994;353(3):246-50.
1994: Jolkkonen J; Jenner P; Marsden C D
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment.
Neuroscience letters 1994;180(2):273-6.
1994: MacKenzie G M; Rose S; Bland-Ward P A; Moore P K; Jenner P; Marsden C D
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole.
Neuroreport 1994;5(15):1993-6.
1994: Sian J; Dexter D T; Lees A J; Daniel S; Jenner P; Marsden C D
Glutathione-related enzymes in brain in Parkinson's disease.
Annals of neurology 1994;36(3):356-61.
1994: Sian J; Dexter D T; Lees A J; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden C D
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Annals of neurology 1994;36(3):348-55.
1994: Jenner P
Oxidative damage in neurodegenerative disease.
Lancet 1994;344(8925):796-8.
1994: Dexter D T; Nanayakkara I; Goss-Sampson M A; Muller D P; Harding A E; Marsden C D; Jenner P
Nigral dopaminergic cell loss in vitamin E deficient rats.
Neuroreport 1994;5(14):1773-6.
1994: Fernandez A; de Ceballos M L; Jenner P; Marsden C D
Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients.
Neuroscience 1994;61(1):73-9.
1994: Rose S; Hindmarsh J G; Steiger M J; Bhatt M; Quinn N P; Jenner P; Marsden C D
Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease.
Clinical neuropharmacology 1994;17(3):260-9.
1994: Gnanalingham K K; Hunter A J; Jenner P; Marsden C D
An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat.
Neuropharmacology 1994;33(5):647-55.
1994: Rose S; Jenner P; Marsden C D
Chronic administration does not alter the accumulation of L-dopa into muscle.
Movement disorders : official journal of the Movement Disorder Society 1994;9(2):167-72.
1994: Dexter D T; Holley A E; Flitter W D; Slater T F; Wells F R; Daniel S E; Lees A J; Jenner P; Marsden C D
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study.
Movement disorders : official journal of the Movement Disorder Society 1994;9(1):92-7.
1993: de Ceballos M L; Fernandez A; Jenner P; Marsden C D
Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients.
Neuroscience letters 1993;160(2):163-6.
1993: Rose S; Jenner P; Marsden C D
Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
The Journal of pharmacy and pharmacology 1993;45(8):725-30.
1993: Gnanalingham K K; Smith L A; Hunter A J; Jenner P; Marsden C D
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Synapse (New York, N.Y.) 1993;14(2):184-94.
1993: Blunt S B; Jenner P; Marsden C D
Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):129-33.
1993: Cicin-Sain L; Jenner P
Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats.
Journal of the neurological sciences 1993;115(1):105-10.
1993: Rose S; Nomoto M; Jackson E A; Gibb W R; Jaehnig P; Jenner P; Marsden C D
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
European journal of pharmacology 1993;230(2):177-85.
1993: Lange K W; Wells F R; Jenner P; Marsden C D
Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease.
Journal of neurochemistry 1993;60(1):197-203.
1993: Dexter D T; Sian J; Jenner P; Marsden C D
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
Advances in neurology 1993;60():273-81.
1993: Jenner P
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
Acta neurologica Scandinavica. Supplementum 1993;146():6-13.
1993: Jenner P
Presymptomatic detection of Parkinson's disease.
Journal of neural transmission. Supplementum 1993;40():23-36.
1993: Collins P; Broekkamp C L; Jenner P; Marsden C D
Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains.
Psychopharmacology 1993;112(4):437-44.
1993: Collins P; Broekkamp C L; Jenner P; Marsden C D
Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat.
Psychopharmacology 1993;112(4):428-36.
1992: Jenner P; Schapira A H; Marsden C D
New insights into the cause of Parkinson's disease.
Neurology 1992;42(12):2241-50.
1992: Kebabian J W; Britton D R; DeNinno M P; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
European journal of pharmacology 1992;229(2-3):203-9.
1992: Dexter D T; Ward R J; Wells F R; Daniel S E; Lees A J; Peters T J; Jenner P; Marsden C D
Alpha-tocopherol levels in brain are not altered in Parkinson's disease.
Annals of neurology 1992;32(4):591-3.
1992: Takeuchi Y; Sawada T; Blunt S; Jenner P; Marsden C D
Transplantation of embryonic mesencephalic and medullary raphe neurons to the neostriatum of rats with unilateral 6-hydroxydopamine lesions.
Brain research 1992;592(1-2):129-34.
1992: Fernandez A; de Ceballos M L; Jenner P; Marsden C D
Striatal neuropeptide levels in Parkinson's disease patients.
Neuroscience letters 1992;145(2):171-4.
1992: Taylor M D; De Ceballos M L; Rose S; Jenner P; Marsden C D
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
European journal of pharmacology 1992;219(2):183-92.
1992: Thomas K L; Rose S; Jenner P; Marsden C D
Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum.
Biochemical pharmacology 1992;44(1):83-91.
1992: Thomas K L; Rose S; Jenner P; Marsden C D
Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
Biochemical pharmacology 1992;44(1):73-82.
1992: Blunt S B; Jenner P; Marsden C D
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
Brain research 1992;582(2):299-311.
1992: Takeuchi Y; Sawada T; Jenner P
Early monoaminergic dysfunction.
Brain & development 1992;14 Suppl():S131-7.
1992: Jenner P
What process causes nigral cell death in Parkinson's disease?
Neurologic clinics 1992;10(2):387-403.
1992: Cheng C H; Costall B; Hamburger M; Hostettmann K; Naylor R J; Wang Y; Jenner P
Toxic effects of solstitialin A 13-acetate and cynaropicrin from Centaurea solstitialis L. (Asteraceae) in cell cultures of foetal rat brain.
Neuropharmacology 1992;31(3):271-7.
1992: Lange K W; Löschmann P A; Wachtel H; Horowski R; Jähnig P; Jenner P; Marsden C D
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
European journal of pharmacology 1992;212(2-3):247-52.
1992: Lange K W; Javoy-Agid F; Agid Y; Jenner P; Marsden C D
Brain muscarinic cholinergic receptors in Huntington's disease.
Journal of neurology 1992;239(2):103-4.
1992: Jenner P
Parkinson's disease: pathological mechanisms and actions of piribedil.
Journal of neurology 1992;239 Suppl 1():S2-8.
1992: Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden C D; Agnoli A
Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1992;7(3):249-56.
1992: Blunt S B; Jenner P; Marsden C D
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1992;88(2):326-40.
1992: Dexter D T; Jenner P; Schapira A H; Marsden C D
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.
Annals of neurology 1992;32 Suppl():S94-100.
1992: Jenner P; Dexter D T; Sian J; Schapira A H; Marsden C D
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
Annals of neurology 1992;32 Suppl():S82-7.
1992: Löschmann P A; Smith L A; Lange K W; Jähnig P; Jenner P; Marsden C D
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.
Psychopharmacology 1992;109(1-2):49-56.
1991: De Ceballos M L; Taylor M D; Jenner P
Isocratic reverse-phase HPLC separation and RIA used in the analysis of neuropeptides in brain tissue.
Neuropeptides 1991;20(3):201-9.
1991: Takeuchi Y; Sawada T; Blunt S; Jenner P; Marsden C D
Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats.
Brain research 1991;562(2):301-5.
1991: Dexter D T; Carayon A; Javoy-Agid F; Agid Y; Wells F R; Daniel S E; Lees A J; Jenner P; Marsden C D
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
Brain : a journal of neurology 1991;114 ( Pt 4)():1953-75.
1991: Walker M J; Jenner P; Marsden C D
A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function.
Biochemical pharmacology 1991;42(4):913-9.
1991: Takeuchi Y; Sawada T; Blunt S; Jenner P; Marsden C D
Serotonergic sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon.
Brain research 1991;551(1-2):171-7.
1991: Rose S; Jenner P; Marsden C D
Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
The Journal of pharmacy and pharmacology 1991;43(5):325-30.
1991: Taylor M D; de Ceballos M L; Jenner P; Marsden C D
Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat.
Biochemical pharmacology 1991;41(9):1385-91.
1991: Lange K W; Wells F R; Rossor M N; Jenner P; Marsden C D
Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(4):373-4.
1991: Blunt S; Jenner P; Marsden C D
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Neuroscience 1991;40(2):453-64.
1991: Löschmann P A; Lange K W; Kunow M; Rettig K J; Jähnig P; Honoré T; Turski L; Wachtel H; Jenner P; Marsden C D
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1991;3(3):203-13.
1991: Jenner P
Oxidative stress as a cause of Parkinson's disease.
Acta neurologica Scandinavica. Supplementum 1991;136():6-15.
1991: Taylor M D; de Ceballos M L; Rose S; Chong P N; Jenner P; Marsden C D
Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
Journal of neural transmission. Parkinson's disease and dementia section 1991;3(2):99-108.
1991: Löschmann P A; Smith L A; Lange K W; Jaehnig P; Jenner P; Marsden C D
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.
Psychopharmacology 1991;105(3):303-9.
1991: Blunt S B; Jenner P; Marsden C D
The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography.
Neuroscience 1991;43(1):95-110.
1991: Collins P; Broekkamp C L; Jenner P; Marsden C D
Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation.
Psychopharmacology 1991;103(4):503-12.
1990: Schapira A H; Mann V M; Cooper J M; Dexter D; Daniel S E; Jenner P; Clark J B; Marsden C D
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.
Journal of neurochemistry 1990;55(6):2142-5.
1990: Mann V M; Cooper J M; Javoy-Agid F; Agid Y; Jenner P; Schapira A H
Mitochondrial function and parental sex effect in Huntington's disease.
Lancet 1990;336(8717):749.
1990: Maret G; el Tayar N; Carrupt P A; Testa B; Jenner P; Baird M
Toxication of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and analogs by monoamine oxidase. A structure-reactivity relationship study.
Biochemical pharmacology 1990;40(4):783-92.
1990: Dexter D T; Carayon A; Vidailhet M; Ruberg M; Agid F; Agid Y; Lees A J; Wells F R; Jenner P; Marsden C D
Decreased ferritin levels in brain in Parkinson's disease.
Journal of neurochemistry 1990;55(1):16-20.
1990: Rose S; Nomoto M; Jackson E A; Gibb W R; Jenner P; Marsden C D
1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset.
European journal of pharmacology 1990;181(1-2):97-103.
1990: Schapira A H; Cooper J M; Dexter D; Clark J B; Jenner P; Marsden C D
Mitochondrial complex I deficiency in Parkinson's disease.
Journal of neurochemistry 1990;54(3):823-7.
1990: Raisman-Vozari R; Girault J A; Moussaoui S; Feuerstein C; Jenner P; Marsden C D; Agid Y
Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.
Brain research 1990;507(1):45-50.
1990: Maret G; Testa B; Jenner P; el Tayar N; Carrupt P A
The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
Drug metabolism reviews 1990;22(4):291-332.
1990: Blunt S B; Jenner P; Marsden C D
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Progress in brain research 1990;82():493-8.
1990: Schapira A H; Holt I J; Sweeney M; Harding A E; Jenner P; Marsden C D
Mitochondrial DNA analysis in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1990;5(4):294-7.
1990: Davis A; Jenner P; Marsden C D
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour.
Psychopharmacology 1990;100(1):19-26.
1990: de Ceballos M L; Jenner P; Marsden C D
Increased [Met]enkephalin and decreased substance P in spinal cord following thermal injury to one limb.
Neuroscience 1990;36(3):731-6.
1989: Lange K W; Wells F R; Rossor M N; Jenner P; Marsden C D
Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease.
British journal of pharmacology 1989;98 Suppl():817P.
1989: Rose S; Thomas K; Jenner P; Marsden C D
Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
British journal of pharmacology 1989;98 Suppl():816P.
1989: Collins P; Broekkamp C L; Jenner P; Marsden C D
D1 or D2 receptor-induced purposeless chewing in rats is differentially modulated by cholinergic drugs.
British journal of pharmacology 1989;98 Suppl():815P.
1989: Rose S; Nomoto M; Jenner P; Marsden C D
Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets.
Biochemical pharmacology 1989;38(21):3677-81.
1989: Lange K W; Wells F R; Rossor M N; Jenner P; Marsden C D
Brain muscarinic receptors in Alzheimer's and Parkinson's diseases.
Lancet 1989;2(8674):1279.
1989: Rose S; Nomoto M; Jackson E A; Gibb W R; Jenner P; Marsden C D
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Neuropharmacology 1989;28(11):1211-6.
1989: Ueki A; Chong P N; Albanese A; Rose S; Chivers J K; Jenner P; Marsden C D
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Neuropharmacology 1989;28(10):1089-97.
1989: Saggu H; Cooksey J; Dexter D; Wells F R; Lees A; Jenner P; Marsden C D
A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.
Journal of neurochemistry 1989;53(3):692-7.
1989: Löschmann P A; Chong P N; Nomoto M; Tepper P G; Horn A S; Jenner P; Marsden C D
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.
European journal of pharmacology 1989;166(3):373-80.
1989: Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden C D
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Neuroscience letters 1989;101(3):305-10.
1989: Dexter D T; Wells F R; Lees A J; Agid F; Agid Y; Jenner P; Marsden C D
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
Journal of neurochemistry 1989;52(6):1830-6.
1989: Jenner P
Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1989;Suppl():22-8.
1989: Jackson E A; Jenner P; Marsden C D
Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra.
Neuropharmacology 1989;28(6):543-55.
1989: Schapira A H; Cooper J M; Dexter D; Jenner P; Clark J B; Marsden C D
Mitochondrial complex I deficiency in Parkinson's disease.
Lancet 1989;1(8649):1269.
1989: Stewart B R; Jenner P; Marsden C D
Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs.
European journal of pharmacology 1989;162(1):101-7.
1989: Dexter D T; Carter C J; Wells F R; Javoy-Agid F; Agid Y; Lees A; Jenner P; Marsden C D
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
Journal of neurochemistry 1989;52(2):381-9.
1989: Chivers J K; Reavill C; Jenner P; Marsden C D
Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs.
The Journal of pharmacy and pharmacology 1989;41(2):106-11.
1989: Dexter D T; Jenner P; Marsden C D
Oxyferriscorbone elevates the total iron content of blood but not brain.
Movement disorders : official journal of the Movement Disorder Society 1989;4(2):176-82.
1989: Stewart B R; Jenner P; Marsden C D
Assessment of the muscarinic receptor subtype involved in the mediation of pilocarpine-induced purposeless chewing behaviour.
Psychopharmacology 1989;97(2):228-34.
1989: Gibb W R; Terruli M; Lees A J; Jenner P; Marsden C D
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Movement disorders : official journal of the Movement Disorder Society 1989;4(1):53-74.
1988: Temlett J A; Chong P N; Oertel W H; Jenner P; Marsden C D
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
European journal of pharmacology 1988;156(2):197-206.
1988: Nomoto M; Jenner P; Marsden C D
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
Neuroscience letters 1988;93(2-3):275-80.
1988: Mesnil M; Testa B; Jenner P
Ex vivo inhibition of rat brain cytochrome P-450 activity by stiripentol.
Biochemical pharmacology 1988;37(19):3619-22.
1988: Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel J J; Marsden C D; Legrand J C; Agid Y
Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
Neuropeptides 1988;12(3):105-10.
1988: Mesnil M; Testa B; Jenner P
In vitro inhibition by stiripentol of rat brain cytochrome P-450-mediated naphthalene hydroxylation.
Xenobiotica; the fate of foreign compounds in biological systems 1988;18(9):1097-106.
1988: Chivers J K; Reavill C; Jenner P; Marsden C D
Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
The Journal of pharmacy and pharmacology 1988;40(9):613-9.
1988: Horton R W; Lowther S; Chivers J; Jenner P; Marsden C D; Testa B
The interaction of substituted benzamides with brain benzodiazepine binding sites in vitro.
British journal of pharmacology 1988;94(4):1234-40.
1988: Aubby D; Saggu H K; Jenner P; Quinn N P; Harding A E; Marsden C D
Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders.
Journal of neurology, neurosurgery, and psychiatry 1988;51(7):893-902.
1988: Willoughby J; Glover V; Sandler M; Albanese A; Jenner P; Marsden C D
Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity.
Neuroscience letters 1988;90(1-2):100-6.
1988: Chivers J K; Gommeren W; Leysen J E; Jenner P; Marsden C D
Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.
The Journal of pharmacy and pharmacology 1988;40(6):415-21.
1988: Hong M; Roots E J; Jenner P; Marsden C D
The effect of long-term treatment with amine-depleting drugs or chlorpromazine on alpha-adrenoreceptors and 5-HT2 receptors in the brain of the rat.
Neuropharmacology 1988;27(5):519-27.
1988: Albanese A; Jenner P; Marsden C D; Stephenson J D
Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neuroscience letters 1988;87(1-2):46-50.
1988: Reavill C; Jenner P; Kumar R; Stolerman I P
High affinity binding of [3H] (-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine.
Neuropharmacology 1988;27(3):235-41.
1988: Rose S; Jenner P; Marsden C D
The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Movement disorders : official journal of the Movement Disorder Society 1988;3(2):117-25.
1988: Stewart B R; Jenner P; Marsden C D
The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat.
Psychopharmacology 1988;96(1):55-62.
1988: Jenner P; Boyce S; Marsden C D
Receptor changes during chronic dopaminergic stimulation.
Journal of neural transmission. Supplementum 1988;27():161-75.
1988: Stewart B R; Rupniak N M; Jenner P; Marsden C D
Animal models of neuroleptic-induced acute dystonia.
Advances in neurology 1988;50():343-59.
1988: Jenner P; Marsden C D
Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
Advances in neurology 1988;49():417-31.
1987: Van de Waterbeemd H; Testa B; Marrel C; Cooper D R; Jenner P; Marsden C D
Multivariate statistical analysis of L-dopa esters as potential anti-parkinsonian prodrugs.
Drug design and delivery 1987;2(2):135-43.
1987: Testa B; Jenner P; Kilpatrick G J; el Tayar N; Van de Waterbeemd H; Marsden C D
Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors?
Biochemical pharmacology 1987;36(23):4041-6.
1987: Waters C M; Hunt S P; Jenner P; Marsden C D
An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Neuroscience 1987;23(3):1025-39.
1987: Dexter D T; Wells F R; Agid F; Agid Y; Lees A J; Jenner P; Marsden C D
Increased nigral iron content in postmortem parkinsonian brain.
Lancet 1987;2(8569):1219-20.
1987: Roselaar S E; Langdon N; Lock C B; Jenner P; Parkes J D
Selegiline in narcolepsy.
Sleep 1987;10(5):491-5.
1987: Stewart B; Rose S; Jenner P; Marsden C D
Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT.
European journal of pharmacology 1987;142(1):173-6.
1987: Cooper D R; Marrel C; van de Waterbeemd H; Testa B; Jenner P; Marsden C D
L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice.
The Journal of pharmacy and pharmacology 1987;39(10):809-18.
1987: Jenner P; Marsden C D
Neuroleptic-induced tardive dyskinesia.
Acta psychiatrica Belgica 1987;87(5):566-98.
1987: Testa B; el Tayar N; Carrupt P A; Van de Waterbeemd H; Kilpatrick G J; Jenner P; Marsden C D
The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses.
The Journal of pharmacy and pharmacology 1987;39(9):767-8.
1987: Hong M; Kilpatrick G J; Jenner P; Marsden C D
Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat.
Neuropharmacology 1987;26(8):1061-9.
1987: Cooper D R; Marrel C; van de Waterbeemd H; Testa B; Jenner P; Marsden C D
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
The Journal of pharmacy and pharmacology 1987;39(8):627-35.
1987: Jenner P; Marsden C D
Chronic pharmacological manipulation of dopamine receptors in brain.
Neuropharmacology 1987;26(7B):931-40.
1987: Waters C M; Hunt S P; Jenner P; Marsden C D
Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Brain research 1987;412(2):244-53.
1987: Dexter D T; Boyce S; Jenner P; Marsden C D
Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex.
Neuroscience letters 1987;76(3):368-71.
1987: Gibb C; Willoughby J; Glover V; Sandler M; Testa B; Jenner P; Marsden C D
Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary.
Neuroscience letters 1987;76(3):316-22.
1987: Dewar D; Jenner P; Marsden C D
Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus.
Biochemical pharmacology 1987;36(10):1738-41.
1987: Weller M E; Rose S; Jenner P; Marsden C D
In vitro characterisation of dopamine receptors in the superior colliculus of the rat.
Neuropharmacology 1987;26(4):347-54.
1987: De Ceballos M L; Boyce S; Taylor M; Jenner P; Marsden C D
Age-related decreases in the concentration of Met- and Leu-enkephalin and neurotensin in the basal ganglia of rats.
Neuroscience letters 1987;75(1):113-7.
1987: Kelly E; Jenner P; Marsden C D
Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats.
The Journal of pharmacy and pharmacology 1987;39(3):196-202.
1987: Chivers J; Jenner P; Marsden C D
Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]-spiperone.
British journal of pharmacology 1987;90(3):467-78.
1987: Hong M; Jenner P; Marsden C D
Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.
Neuropharmacology 1987;26(2-3):237-45.
1987: Rupniak N M; Prestwich S A; Horton R W; Jenner P; Marsden C D
Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine.
Journal of neural transmission 1987;68(1-2):113-25.
1987: Marion M H; Stocchi F; Quinn N P; Jenner P; Marsden C D
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Advances in neurology 1987;45():493-6.
1987: Marion M H; Stocchi F; Malcolm S L; Quinn N P; Jenner P; Marsden C D
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
European neurology 1987;27 Suppl 1():54-8.
1987: Gibb W R; Lees A J; Wells F R; Barnard R O; Jenner P; Marsden C D
Pathology of MPTP in the marmoset.
Advances in neurology 1987;45():187-90.
1987: Nomoto M; Stahl S; Jenner P; Marsden C D
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Movement disorders : official journal of the Movement Disorder Society 1987;2(1):37-45.
1987: Moser A; Reavill C; Liebetrau A; Jenner P; Marsden C D; Cramer H
Dopamine and somatostatin modulated adenylate cyclase activity in the rat caudate-putamen following unilateral cortical ablation.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1987;68(2):406-10.
1987: Jenner P; Rose S; Nomoto M; Marsden C D
MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
Advances in neurology 1987;45():183-6.
1986: Kilpatrick G J; Jenner P; Marsden C D
[3H]SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas.
The Journal of pharmacy and pharmacology 1986;38(12):907-12.
1986: De Ceballos M L; Boyce S; Jenner P; Marsden C D
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
European journal of pharmacology 1986;130(3):305-9.
1986: Jenner P; Taquet H; Mauborgne A; Benoliel J T; Cesselin F; Rose S; Javoy-Agid F; Agid Y; Marsden C D
Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
Journal of neurochemistry 1986;47(5):1548-51.
1986: Simpson M D; Jenner P; Marsden C D
Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat.
Biochemical pharmacology 1986;35(20):3501-6.
1986: Simpson M D; Jenner P; Marsden C D
Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat.
Biochemical pharmacology 1986;35(19):3203-8.
1986: Kilpatrick G J; el Tayar N; Van de Waterbeemd H; Jenner P; Testa B; Marsden C D
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors.
Molecular pharmacology 1986;30(3):226-34.
1986: Dexter D; Carter C; Agid F; Agid Y; Lees A J; Jenner P; Marsden C D
Lipid peroxidation as cause of nigral cell death in Parkinson's disease.
Lancet 1986;2(8507):639-40.
1986: Repond C; Pratt J A; Stolerman I P; Mayer J M; Jenner P; Marsden C D; Testa B
Affinity of pyridylalkylamines for nicotinic, muscarinic and histaminic recognition sites in brain tissue preparations.
Arzneimittel-Forschung 1986;36(8):1191-4.
1986: De Ceballos M L; Jenner P; Marsden C D
Acute and repeated administration of sulpiride alters Met-and Leu-enkephalin content of rat brain.
Neuroscience letters 1986;68(3):322-6.
1986: Kilpatrick G J; Jenner P; Marsden C D
[125I]Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D-2 receptor from rat striatum.
The Journal of pharmacy and pharmacology 1986;38(5):406-8.
1986: Gibb W R; Lees A J; Jenner P; Marsden C D
The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset.
Neuroscience letters 1986;65(1):79-83.
1986: Kilpatrick G J; Jenner P; Marsden C D
Specific [3H]piflutixol binding to CHAPS-solubilised rat striatal preparations involves dopamine D-2 but not D-1 binding sites.
Journal of neurochemistry 1986;46(2):413-21.
1986: Nomoto M; Jenner P; Marsden C D
Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset.
European journal of pharmacology 1986;121(1):123-8.
1986: Davis A S; Jenner P; Marsden C D
A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine.
British journal of pharmacology 1986;87(1):129-37.
1986: Bradbury A J; Costall B; Domeney A M; Jenner P; Kelly M E; Marsden C D; Naylor R J
1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
Nature 1986;319(6048):56-7.
1986: Muscatt S; Rothwell J; Obeso J; Leigh N; Jenner P; Marsden C D
Urea-induced stimulus-sensitive myoclonus in the rat.
Advances in neurology 1986;43():553-63.
1986: Rupniak N M; Briggs R S; Petersen M M; Mann S; Reavill C; Jenner P; Marsden C D
Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine.
Clinical neuropharmacology 1986;9(3):282-92.
1986: Marion M H; Stocchi F; Quinn N P; Jenner P; Marsden C D
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
Clinical neuropharmacology 1986;9(2):165-81.
1986: de Ceballos M L; Baker M; Rose S; Jenner P; Marsden C D
Do enkephalins in basal ganglia mediate a physiological motor rest mechanism?
Movement disorders : official journal of the Movement Disorder Society 1986;1(4):223-33.
1986: Garvey J; Petersen M; Waters C M; Rose S P; Hunt S; Briggs R; Jenner P; Marsden C D
Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
Movement disorders : official journal of the Movement Disorder Society 1986;1(2):129-34.
1986: Jenner P; Marsden C D
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Journal of neural transmission. Supplementum 1986;20():11-39.
1986: Moser A; Reavill C; Jenner P; Marsden C D; Cramer H
Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1986;62(3):567-71.
1986: Rupniak N M; Jenner P; Marsden C D
Acute dystonia induced by neuroleptic drugs.
Psychopharmacology 1986;88(4):403-19.
1986: Jenner P; Pratt J A; Marsden C D
Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT.
Advances in neurology 1986;43():629-43.
1986: Pratt J A; Rothwell J; Jenner P; Marsden C D
p,p'-DDT-induced myoclonus in the rat and its application as an animal model of 5-HT-sensitive action myoclonus.
Advances in neurology 1986;43():577-88.
1986: Luscombe G; Jenner P; Marsden C D
5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action.
Advances in neurology 1986;43():529-43.
1986: Chadwick D; Hallett M; Jenner P; Marsden C D
Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder.
Advances in neurology 1986;43():183-90.
1985: Testa B; Naylor R; Costall B; Jenner P; Marsden C D
Does an endogenous methylpyridinium analogue cause Parkinson's disease?
The Journal of pharmacy and pharmacology 1985;37(9):679-80.
1985: Rupniak N M; Hall M D; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden C D
Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
Biochemical pharmacology 1985;34(15):2755-63.
1985: Kelly E; Jenner P; Marsden C D
The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices.
Biochemical pharmacology 1985;34(15):2655-62.
1985: Fine A; Reynolds G P; Nakajima N; Jenner P; Marsden C D
Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset.
Neuroscience letters 1985;58(1):123-6.
1985: Kelly E; Jenner P; Marsden C D
Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro.
Journal of neurochemistry 1985;45(1):137-44.
1985: Nomoto M; Jenner P; Marsden C D
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Neuroscience letters 1985;57(1):37-41.
1985: Pratt J A; Rothwell J; Jenner P; Marsden C D
Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function.
Neuropharmacology 1985;24(5):361-73.
1985: Kelly E; Jenner P; Marsden C D
Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones.
Neuroscience letters 1985;56(1):57-62.
1985: Dewar D; Jenner P; Marsden C D
Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus.
Neuroscience 1985;15(1):41-6.
1985: Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden C D
SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Biochemical pharmacology 1985;34(10):1665-9.
1985: Kilpatrick G J; Jenner P; Marsden C D
Properties of rat striatal D-2 dopamine receptors solubilized with the zwitterionic detergent CHAPS.
The Journal of pharmacy and pharmacology 1985;37(5):320-8.
1985: Pratt J A; Jenner P; Marsden C D
Comparison of the effects of benzodiazepines and other anticonvulsant drugs on synthesis and utilization of 5-HT in mouse brain.
Neuropharmacology 1985;24(1):59-68.
1985: Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden C D
Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats.
Psychopharmacology 1985;86(1-2):228-32.
1985: Jenner P; Rupniak N M; Marsden C D
Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.
Psychopharmacology. Supplementum 1985;2():174-81.
1985: Rupniak N M; Hall M D; Kelly E; Fleminger S; Kilpatrick G; Jenner P; Marsden C D
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs.
Journal of neural transmission 1985;62(3-4):249-66.
1985: Rupniak N M; Jenner P; Marsden C D
Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.
Psychopharmacology 1985;85(1):71-9.
1984: Kilpatrick G J; Jenner P; Marsden C D
The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes.
European journal of pharmacology 1984;107(1):71-8.
1984: Pratt J A; Jenner P; Johnson A L; Shorvon S D; Reynolds E H
Anticonvulsant drugs alter plasma tryptophan concentrations in epileptic patients: implications for antiepileptic action and mental function.
Journal of neurology, neurosurgery, and psychiatry 1984;47(10):1131-3.
1984: Rupniak N M; Jenner P; Marsden C D
Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatment.
Neuroscience letters 1984;50(1-3):63-5.
1984: Luscombe G; Jenner P; Marsden C D
Correlation of [3H]5-hydroxytryptamine (5HT) binding to brain stem preparations and the production and prevention of myoclonus in guinea pig by 5HT agonists and antagonists.
European journal of pharmacology 1984;104(3-4):235-44.
1984: Jenner P; Rupniak N M; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden C D
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Neuroscience letters 1984;50(1-3):85-90.
1984: Rupniak N M; Boyce S; Jenner P; Marsden C D
Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluorperazine for 15 months.
Neuropharmacology 1984;23(8):893-8.
1984: Chivers J K; Hall M D; Kelly E; Jenner P; Marsden C D
Dopamine receptor binding sites in the rat superior colliculus.
The Journal of pharmacy and pharmacology 1984;36(7):484-8.
1984: Boyce S; Kelly E; Reavill C; Jenner P; Marsden C D
Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.
Biochemical pharmacology 1984;33(11):1747-52.
1984: Murugaiah K; Fleminger S; Hall M D; Theodorou A; Jenner P; Marsden C D
Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats.
Neuropharmacology 1984;23(6):599-609.
1984: Hall M D; Cooper D R; Fleminger S; Rupniak N M; Jenner P; Marsden C D
Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
Neuropharmacology 1984;23(5):545-53.
1984: Kerwin R; Rupniak N M; Jenner P; Marsden C D
Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine.
Neuroscience letters 1984;45(3):329-34.
1984: Luscombe G; Jenner P; Marsden C D
5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors.
Neuroscience letters 1984;44(3):241-6.
1984: Kerwin R W; Rupniak N M; Jenner P; Marsden C D
A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices.
Neuroscience 1984;11(1):205-10.
1984: Cooper D R; Marrel C; Testa B; van de Waterbeemd H; Quinn N; Jenner P; Marsden C D
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Clinical neuropharmacology 1984;7(1):89-98.
1984: Kelly E; Jenner P; Marsden C D
Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1984;55(2):243-52.
1984: Reavill C; Muscatt S; Leigh P N; Jenner P; Marsden C D
Enhanced GABA function in the angular complex (lateral periaqueductal grey matter and adjacent reticular formation) alters the postural component of striatal- or nigral-derived circling.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1984;56(1):1-11.
1984: Rupniak N M; Kilpatrick G; Hall M D; Jenner P; Marsden C D
Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
Psychopharmacology 1984;84(4):512-9.
1984: Rupniak N M; Mann S; Hall M D; Fleminger S; Kilpatrick G; Jenner P; Marsden C D
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
Psychopharmacology 1984;84(4):503-11.
1984: Jenner P; Marsden C D
Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs.
Acta psychiatrica Scandinavica. Supplementum 1984;311():109-23.
1984: Reavill C; Jenner P; Marsden C D
Gamma-aminobutyric acid and basal ganglia outflow pathways.
Ciba Foundation symposium 1984;107():164-76.
1983: Murugaiah K; Theodorou A; Jenner P; Marsden C D
Alterations in cerebral dopamine function caused by administration of cis- or trans-flupenthixol for up to 18 months.
Neuroscience 1983;10(3):811-9.
1983: Hall M D; Jenner P; Marsden C D
Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration.
Biochemical pharmacology 1983;32(19):2973-7.
1983: Fleminger S; Rupniak N M; Hall M D; Jenner P; Marsden C D
Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Biochemical pharmacology 1983;32(19):2921-7.
1983: Murugaiah K; Fleminger S; Theodorou A; Jenner P; Marsden C D
Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake.
Biochemical pharmacology 1983;32(17):2495-9.
1983: Rupniak N; Hong M; Mansfield S; Fleminger S; Dyer R; Jenner P; Marsden C D
Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
European journal of pharmacology 1983;93(3-4):195-200.
1983: Hall M D; Jenner P; Kelly E; Marsden C D
Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
British journal of pharmacology 1983;79(2):599-610.
1983: Luscombe G; Jenner P; Marsden C D
Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs.
Biochemical pharmacology 1983;32(12):1857-64.
1983: Fleminger S; van de Waterbeemd H; Rupniak N M; Reavill C; Testa B; Jenner P; Marsden C D
Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat.
The Journal of pharmacy and pharmacology 1983;35(6):363-8.
1983: Reynolds G P; Garrett N J; Rupniak N; Jenner P; Marsden C D
Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors.
European journal of pharmacology 1983;89(3-4):325-6.
1983: Rupniak M N; Jenner P; Marsden C D
The effect of chronic neuroleptic administration on cerebral dopamine receptor function.
Life sciences 1983;32(20):2289-311.
1983: Theodorou A E; Jenner P; Marsden C D
Cation specificity of 3H-sulpiride binding involves alteration in the number of striatal binding sites.
Life sciences 1983;32(11):1243-54.
1983: Reavill C; Jenner P; Marsden C D
Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways.
Biochemical pharmacology 1983;32(5):865-70.
1983: Reynolds L M; Dyer R G; Jenner P; Marsden C D
Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration.
The Journal of pharmacy and pharmacology 1983;35(3):170-4.
1983: Hall M D; Jenner P; Marsden C D
Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine.
European journal of pharmacology 1983;87(1):85-94.
1983: Dewar D; Jenner P; Marsden C D
Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1983;52(2):281-92.
1983: Leigh P N; Reavill C; Jenner P; Marsden C D
Basal ganglia outflow pathways and circling behaviour in the rat.
Journal of neural transmission 1983;58(1-2):1-41.
1983: Jenner P; Sheehy M; Marsden C D
Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.
British journal of clinical pharmacology 1983;15 Suppl 2():277S-289S.
1983: Jenner P; Kerwin R; Rupniak N M; Murugaiah K; Hall M D; Fleminger S; Marsden C D
Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
Journal of neural transmission. Supplementum 1983;18():205-12.
1983: Rupniak N M; Jenner P; Marsden C D
Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats.
Psychopharmacology 1983;79(2-3):226-30.
1982: Luscombe G; Jenner P; Marsden C D
Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems.
Neuropharmacology 1982;21(12):1257-65.
1982: Fleminger S; Jenner P; Marsden C D
Are dopamine receptors present on human lymphocytes?
The Journal of pharmacy and pharmacology 1982;34(10):658-63.
1982: Murugaiah K; Mann S; Theodorou A E; Jenner P; Marsden C D
Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors.
Life sciences 1982;31(2):181-8.
1982: Luscombe G; Jenner P; Marsden C D
Myoclonus in guniea pigs is induced by indole-containing but not piperazine-containing 5HT agonists.
Life sciences 1982;30(17):1487-94.
1982: Murugaiah K; Theodorou A; Mann S; Clow A; Jenner P; Marsden C D
Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum.
Nature 1982;296(5857):570-2.
1982: Jenner P; Hall M D; Murugaiah K; Rupniak N; Theodorou A; Marsden C D
Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.
Biochemical pharmacology 1982;31(3):325-8.
1982: Marsden C D; Jefferson D; Leigh N; Jenner P
Plasma propranolol in essential tremor.
Annals of neurology 1982;11(1):107.
1982: Jenner P; Marsden C D
The mode of action of sulpiride as an atypical antidepressant agent.
Advances in biochemical psychopharmacology 1982;32():85-103.
1982: Jenner P; Theodorou A; Marsden C D
Specific receptors for substituted benzamide drugs in brain.
Advances in biochemical psychopharmacology 1982;35():109-41.
1981: Taylor R J; Reavill C; Jenner P; Marsden C D
Circling behavior following unilateral kainic acid injections into rat striatum.
European journal of pharmacology 1981;76(2-3):211-22.
1981: Reavill C; Leigh P N; Jenner P; Marsden C D
Drug-induced circling after unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway is mediated via the midbrain periaqueductal grey and adjacent reticular formation (angular complex).
Life sciences 1981;29(23):2357-65.
1981: Jenner P; Marsden C D
Substituted benzamide drugs as selective neuroleptic agents.
Neuropharmacology 1981;20(12B):1285-93.
1981: Jenner P; Rupniak N M; Hall M D; Dyer R; Leigh N; Marsden C D
Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
European journal of pharmacology 1981;76(1):31-6.
1981: Luscombe G; Jenner P; Marsden C D
Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain.
Neuropharmacology 1981;20(9):819-31.
1981: Rupniak N M; Jenner P; Marsden C D
The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine-sensitive adenylate cyclase.
The Journal of pharmacy and pharmacology 1981;33(9):602-3.
1981: Theodorou A; Reavill C; Jenner P; Marsden C D
Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D-2 receptors exist post-synaptically on corticostriate afferents and striatal neurons.
The Journal of pharmacy and pharmacology 1981;33(7):439-44.
1981: Theodorou A; Gommeren W; Clow A; Leysen J; Jenner P; Marsden C D
Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain.
Life sciences 1981;28(14):1621-7.
1981: Kolbe H; Clow A; Jenner P; Marsden C D
Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors.
Neurology 1981;31(4):434-9.
1981: Reavill C; Jenner P; Leigh N; Marsden C D
The role of nigral projections to the thalamus in drug-induced circling behaviour in the rat.
Life sciences 1981;28(13):1457-66.
1981: Dyer R G; Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden C D
During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated.
Life sciences 1981;28(2):167-74.
1981: Reavill C; Leigh N; Jenner P; Marsden C D
Critical role of midbrain reticular formation in the expression of dopamine-mediated circling behaviour.
Advances in biochemical psychopharmacology 1981;30():187-204.
1980: Schachter M; Marsden C D; Parkes J D; Jenner P; Testa B
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
Journal of neurology, neurosurgery, and psychiatry 1980;43(11):1016-21.
1980: Reavill C; Leigh N; Jenner P; Marsden C D
GABA mediated circling from substantia nigra.
Nature 1980;287(5780):368.
1980: Schachter M; Bédard P; Debono A G; Jenner P; Marsden C D; Price P; Parkes J D; Keenan J; Smith B; Rosenthaler J; Horowski R; Dorow R
The role of D-1 and D-2 receptors.
Nature 1980;286(5769):157-9.
1980: Chadwick D; Hallett M; Jenner P; Marsden C D
Observations on chloralose-induced myoclonus in guinea-pigs.
British journal of pharmacology 1980;69(3):535-40.
1980: Theodorou A E; Hall M D; Jenner P; Marsden C D
Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.
The Journal of pharmacy and pharmacology 1980;32(6):441-4.
1980: Jenner P; Marsden C D; Thanki C M
Behavioural changes induced by N,N-dimethyl-tryptamine in rodents.
British journal of pharmacology 1980;69(1):69-80.
1980: Clow A; Theodorou A; Jenner P; Marsden C D
Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
European journal of pharmacology 1980;63(2-3):145-57.
1980: Clow A; Theodorou A; Jenner P; Marsden C D
Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
European journal of pharmacology 1980;63(2-3):135-44.
1980: Reavill C; Jenner P; Marsden C D
Metabolite involvement in bromocriptine-induced circling behaviour in rodents.
The Journal of pharmacy and pharmacology 1980;32(4):278-84.
1980: Marsden C D; Jenner P
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.
Psychological medicine 1980;10(1):55-72.
1980: Clow A; Jenner P; Marsden C D; Theodorou A
Regional changes in brain dopamine receptor function during six months trifluoperazine administration to rats [proceedings]
British journal of pharmacology 1980;68(1):163P-164P.
1980: Jenner P; Clow A; Reavill C; Theodorou A; Marsden C D
Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms.
The Journal of pharmacy and pharmacology 1980;32(1):39-44.
1980: Clow A; Theodorou A; Jenner P; Marsden C D
Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
Advances in biochemical psychopharmacology 1980;24():335-40.
1980: Clow A; Theodorou A; Jenner P; Marsden C D
A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration.
Psychopharmacology 1980;69(3):227-33.
1980: Clow A; Jenner P; Theodorou A; Marsden C D
Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.
Advances in biochemical psychopharmacology 1980;24():53-5.
1979: Jenner P; Leigh N; Marsden C D; Reavill C
Dopamine mediated circling behaviour is modulated by lesions of the ventromedial nucleus of the thalamus [proceedings]
British journal of pharmacology 1979;67(3):432P.
1979: Clow A; Jenner P; Marsden C D; Reavill C; Theodorou A
Stereoselective blockade of cerebral dopamine receptors by sulpiride and sultopride [proceedings]
British journal of pharmacology 1979;67(3):433P.
1979: Jenner P; Marsden C D; Pratt J; Reynolds E H
Modulation of picrotoxin-induced forepaw myoclonus in the rat by benzodiazepines [proceedings]
British journal of pharmacology 1979;67(3):440P.
1979: Jefferson D; Jenner P; Marsden C D
beta-Adrenoreceptor antagonists in essential tremor.
Journal of neurology, neurosurgery, and psychiatry 1979;42(10):904-9.
1979: Reavill C; Leigh N; Jenner P; Marsden C D
Dopamine-mediated circling behaviour does not involve the nigro-tectal pathway.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1979;37(2):309-16.
1979: Pratt J; Jenner P; Reynolds E H; Marsden C D
Clonazepam induces decreased serotoninergic activity in the mouse brain.
Neuropharmacology 1979;18(10):791-9.
1979: Jenner P; Marsden C D
Tardive dyskinesias.
Lancet 1979;2(8148):900.
1979: Jefferson D; Jenner P; Marsden C D
Relationship between plasma propranolol concentration and relief of essential tremor.
Journal of neurology, neurosurgery, and psychiatry 1979;42(9):831-7.
1979: Jenner P; Marsden C D
The substituted benzamides--a novel class of dopamine antagonists.
Life sciences 1979;25(6):479-85.
1979: Clow A; Jenner P; Marsden C D
Changes in dopamine-mediated behaviour during one year's neuroleptic administration.
European journal of pharmacology 1979;57(4):365-75.
1979: Jenner P; Leigh N; Marsden C D; Reavill C
Superior colliculus lesions do not alter dopamine mediated circling behaviour [proceedings]
British journal of pharmacology 1979;66(3):479P-480P.
1979: Clow A; Jenner P; Marsden C D; Pratt J; Reavill C; Thanki C; Theodorou A
Central properties of alpha-allophanyl-alpha-allyl-gamma-valerolactone (valofan) [proceedings]
British journal of pharmacology 1979;66(3):478P-479P.
1979: Chadwick D; Jenner P; Marsden C D
5-Hydroxytryptamine and myoclonus induced by 1,2-di-hydroxybenzene (catechol) in the guinea-pig.
British journal of pharmacology 1979;66(3):358-60.
1979: Theodorou A; Crockett M; Jenner P; Marsden C D
Specific binding of [3H]sulpiride to rat striatal preparations.
The Journal of pharmacy and pharmacology 1979;31(6):424-6.
1979: Jenner P; Marsden C D; Reavill C
Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings]
British journal of pharmacology 1979;66(1):103P-104P.
1979: Reavill C; Jenner P; Leigh N; Marsden C D
Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components.
Neuroscience letters 1979;12(2-3):323-8.
1979: Luscombe G; Clow A; Jenner P; Marsden C D
Antagonism by propranolol of central dopamine receptor stimulation is not related to beta-adrenergic blockade.
The Journal of pharmacy and pharmacology 1979;31(5):355-6.
1979: Jefferson D; Jenner P; Marsden C D
Relationship between plasma propranolol levels and the clinical suppression of essential tremor [proceedings]
British journal of clinical pharmacology 1979;7(4):419P-420P.
1979: Clow A; Jenner P; Theodorou A; Marsden C D
Neuroleptic drugs and the dopamine hypothesis.
Lancet 1979;1(8122):934.
1979: Clow A; Jenner P; Theodorou A; Marsden C D
Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months.
Nature 1979;278(5699):59-61.
1979: Harrison M J; Marsden C D; Jenner P
Effect of experimental ischemia on neurotransmitter amines in the gerbil brain.
Stroke; a journal of cerebral circulation 1979;10(2):165-8.
1978: Elliott P N; Jenner P; Marsden C D
Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs.
The Journal of pharmacy and pharmacology 1978;30(12):788-91.
1978: Jenner P; Marsden C D; Pratt J; Reynolds E H
Altered serotoninergic activity in mouse brain induced by clonazepam [proceedings]
British journal of pharmacology 1978;64(3):432P.
1978: Clow A; Jenner P; Marsden C D
Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]
British journal of pharmacology 1978;64(3):414P.
1978: Dolphin A; Jenner P; Marsden C D
3-Methoxy-4-hydroxyphenylglycol sulphate (MOPEG-SO4) as an index of cerebral noradrenaline turnover following depletion of transmitter stores in the rat.
The Journal of pharmacy and pharmacology 1978;30(9):580-2.
1978: Jenner P; Clow A; Reavill C; Theodorou A; Marsden C D
A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs.
Life sciences 1978;23(6):545-9.
1978: Clow A; Jenner P; Marsden C D
An experimental model of tardive dyskinesias.
Life sciences 1978;23(5):421-3.
1978: Jenner P; Pycock C; Marsden C D
The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity.
Psychopharmacology 1978;58(2):131-6.
1978: Horton R W; Jenner P; Marsden C D; Meldrum B S; Reavill C
Behavioural effects of allylglycine (2-amino-4-pentenoic acid) and 2-keto-4-pentenoic acid following focal injection into the rat cerebellum and caudate nucleus [proceedings]
British journal of pharmacology 1978;63(2):381P.
1978: Jenner P; Marsden C D; Thanki C M
Behavioural changes induced by N,N-dimethyltryptamine in rodents [proceedings]
British journal of pharmacology 1978;63(2):380P.
1978: Chadwick D; Trimble M; Jenner P; Driver M V; Reynolds E H
Manipulation of cerebral monoamines in the treatment of human epilepsy: a pilot study.
Epilepsia 1978;19(1):3-10.
1978: Chadwick D; Gorrod J W; Jenner P; Marsden C D; Reynolds E H
Functional changes in cerebral 5-hydroxytryptamine metabolism in the mouse induced by anticonvulsant drugs.
British journal of pharmacology 1978;62(1):115-24.
1978: Chadwick D; Hallett M; Jenner P; Marsden C D
5-hydroxytryptophan-induced myoclonus in guinea pigs. A physiological and pharmacological investigations.
Journal of the neurological sciences 1978;35(1):157-65.
1978: Jenner P; Elliott P N; Clow A; Reavill C; Marsden C D
A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.
The Journal of pharmacy and pharmacology 1978;30(1):46-8.
1977: Donaldson I M; Dolphin A C; Jenner P; Pycock C; Marsden C D
Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles.
Brain research 1977;138(3):487-509.
1977: Dolphin A C; Jenner P; Sawaya M C; Marsden C D; Testa B
The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents.
The Journal of pharmacy and pharmacology 1977;29(12):727-34.
1977: Jenner P; Marsden C D; Pycock C; Reavill C
Lack of serotoninergic involvement in turning behaviour induced by a unilateral lesion of the locus coeruleus in rats [proceedings]
British journal of pharmacology 1977;61(3):482P.
1977: Sawaya M C; Dolphin A; Jenner P; Marsden C D; Meldrum B S
Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists.
Biochemical pharmacology 1977;26(20):1877-84.
1977: Jenner P; Marsden C D; Pycock C J
Chronic amphetamine administration and central dopamine receptor sensitivity [proceedings]
British journal of pharmacology 1977;61(1):142P.
1977: Dolphin A; Christina M; Sawaya M C; Jenner P; Marsden C D
Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation.
Naunyn-Schmiedeberg's archives of pharmacology 1977;299(2):167-73.
1977: Chadwick D; Hallett M; Harris R; Jenner P; Reynolds E H; Marsden C D
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
Brain : a journal of neurology 1977;100(3):455-87.
1977: Clow A; Elliott P N; Jenner P; Marsden C D; Pycock C
Interactions of substituted benzamide drugs with cerebral dopamine pathways [proceedings]
British journal of pharmacology 1977;60(2):268P-269P.
1977: Chadwick D; Hallet M; Jenner P; Marsden C D
5-Hydroxytryptophan-induced behaviour in guinea-pigs: its relevance to human myoclonus [proceedings]
British journal of clinical pharmacology 1977;4(3):402P-403P.
1977: Elliott P N; Jenner P; Huizing G; Marsden C D; Miller R
Substituted benzamides as cerebral dopamine antagonists in rodents.
Neuropharmacology 1977;16(5):333-42.
1977: Chadwick D; Jenner P; Reynolds E H
Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs.
Annals of neurology 1977;1(3):218-24.
1977: Dolphin A C; Jenner P; Marsden C D; Sawaya M C
Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings].
British journal of pharmacology 1977;59(3):467P.
1977: Galea-Debono A; Jenner P; Marsden C D; Parkes J D; Tarsy D; Walters J
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
Journal of neurology, neurosurgery, and psychiatry 1977;40(2):162-7.
1977: Elliott P N; Jenner P; Chadwick D; Reynolds E; Marsden C D
The effect of diphenylhydantoin on central catecholamine containing neuronal systems.
The Journal of pharmacy and pharmacology 1977;29(1):41-3.
1976: Dolphin A; Jenner P; Marsden C D
Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity.
Pharmacology, biochemistry, and behavior 1976;5(4):431-9.
1976: Donaldson I; Dolphin A; Jenner P; Marsden C D; Pycock C
The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus.
European journal of pharmacology 1976;39(2):179-91.
1976: Dolphin A; Elliott P N; Jenner P
The irritant properties of dopamine-beta-hydroxylase inhibitors in relation to their effects on L-dopa-induced locomotor activity.
The Journal of pharmacy and pharmacology 1976;28(10):782-5.
1976: Donaldson I M; Dolphin A; Jenner P; Marsden C D; Pycock C
The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus.
Brain : a journal of neurology 1976;99(3):427-46.
1976: Elliott P N; Huizing G; Jenner P; Marsden C D; Miller R
Substituted benzamides as dopamine antagonists [proceedings].
British journal of pharmacology 1976;57(3):472P.
1976: Dolphin A C; Jenner P; Marsden C D
The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice.
Pharmacology, biochemistry, and behavior 1976;4(6):661-70.
1976: Donaldson I M; Dolphin A; Jenner P; Marsden C D; Pycock C
Contraversive circling behaviour produced by unilateral electrolytic lesions of the ventral noradrenergic bundle mimicking the changes seen with unilateral electrolytic lesions of the locus coeruleus.
The Journal of pharmacy and pharmacology 1976;28(4):329-31.
1976: Dolphin A C; Elliott P N; Jenner P
Proceedings: Reduction of locomotor activity in mice by dopamine-beta-hydroxylase inhibitors--evidence against the involvement of non-specific irritation.
British journal of pharmacology 1976;56(3):395P.
1976: Donaldson I M; Jenner P; Marsden C D; Miller R; Peringer E
Proceedings: Is metoclopramide a directly acting dopamine receptor antagonist?
British journal of pharmacology 1976;56(3):373P.
1976: Dolphin A; Jenner P; Marsden C D
Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase.
European journal of pharmacology 1976;35(1):135-44.
1975: Reynolds E H; Chadwick D; Jenner P; Chanarin I
Folate and monoamine metabolism in epilepsy.
Journal of the neurological sciences 1975;26(4):605-15.
1975: Dolphin A; Jenner P; Marsden C D
Interference by alphamethylparatyrosine with three procedures for assay of cerebral catecholamines.
Journal of neurochemistry 1975;25(6):897-8.
1975: Jenner P; Chadwick D; Reynolds E H; Marsden C D
Proceedings: Clonazepam-induced changes in 5-hydroxytryptamine (5-HT) metabolism in aminals and man.
The Journal of pharmacy and pharmacology 1975;27 Suppl?-2():38P.
1975: Dolphin A; Jenner P; Marsden C D
Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents.
British journal of pharmacology 1975;55(2):292P.
1975: Donaldson I; Dolphin A; Jenner P; Mardsen C K; Pycock C
Proceedings: The role of dopamine in rotational behaviour produced by unilateral lesions of the locus coeruleus.
British journal of pharmacology 1975;55(2):290P.
1975: Jenner P; Chadwick D; Reynolds E H; Marsden C D
Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin.
The Journal of pharmacy and pharmacology 1975;27(9):707-10.
1975: Chadwick D; Jenner P; Harris R; Reynolds E H; Marsden C D
Manipulation of brain serotonin in the treatment of myoclonus.
Lancet 1975;2(7932):434-5.
1975: Jenner P; Marsden C D
The influence of piribedil (ET495) on components of locomotor activity.
European journal of pharmacology 1975;33(1):211-5.
1975: Gorrod J W; Jenner P
Metabolic N-oxidation products of aliphatic amines as potential mediators in amine pharmacology.
International journal of clinical pharmacology and biopharmacy 1975;12(1-2):180-5.
1975: Jenner P; Marsden C D; Peringer E
Proceedings: Behavioural and biochemical evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.
British journal of pharmacology 1975;54(2):275P-276P.
1975: Dolphin A; Jenner P; Marsden C D
Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia.
British journal of pharmacology 1975;54(2):246P-247P.
1975: Peringer E; Jenner P; Marsden C D
Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine.
The Journal of pharmacy and pharmacology 1975;27(6):442-4.
1975: Chadwick D; Jenner P; Reynolds E H
Letter: Amines, anticonvulsants, and epilepsy.
Lancet 1975;1(7922):1425-6.
1975: Chadwick D; Jenner P; Reynolds E H
Amines, anticonvulsants, and epilepsy.
Lancet 1975;1(7905):473-6.
1975: Dolphin A; Jenner P; Marsden C D; Pycock C; Tarsy D
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.
Psychopharmacologia 1975;41(2):133-8.
1975: Marsden C D; Duvoisin R C; Jenner P; Parkes J D; Pycock C; Tarsy D
Relationship between animal models and clinical parkinsonism.
Advances in neurology 1975;9():165-75.
1974: Marsden C D; Dolphin A; Duvoisin R C; Jenner P; Tarsy D
Role of noradrenaline in levodopa reversal of reserpine akinesia.
Brain research 1974;77(3):521-5.
1973: Jenner P; Taylor A R; Campbell D B
Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent.
The Journal of pharmacy and pharmacology 1973;25(9):749-50.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Peter Jenner

Research Profile (preview)

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Activities & Behaviors

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Peter Jenner (preview)

All Publications